BASF India

Refer to important disclosures at the end of this report

Capturing benefits of economic recovery; maintain Buy

- Reported EBIT/PAT in Q3 were above our estimates by 130%/103%, aided by a sales beat and superior operating delivery in certain segments. Significant growth in Materials, Chemicals and Industrial divisions (35%, 25% & 66%) was driven by pent-up demand and quicker-thanexpected recovery in key end-user industries such as Auto, Consumer Durables, Paints, etc.
- The company delivered the best-in-class reported EBITDA of Rs2.3bn in Q3, led by enhanced segment performance, further aided by lower employee and other costs (as % of sales). Interest costs too have trended lower by 27%, sequentially.
- Robust recovery was seen in operating margins in Materials (12.7% vs. -1% yoy) and Industrial solutions (12.8% vs. 2.6% yoy) after almost 8-10 quarters and was imperative to the overall positive performance. OPM of the Nutrition & Care division too improved significantly to 8.3% vs. -4.9% yoy.
- We remain positive on the overall growth trajectory of the business and believe that sustaining the positive performance in Materials and Industrial solutions is crucial to long-term growth prospects. Factoring in margin improvement of 80-110bps on operational improvement, we raise our EPS estimates for FY22/23 by 19-23% and arrive at a revised TP of Rs1,940 (28x FY23E) from Rs1,630 earlier. We maintain Buy, with EW stance in EAP.

Growth across most segments: Overall, revenues grew 20.4% yoy to Rs24.24bn, driven by healthy demand for Materials (up 35% yoy; better pricing environment and demand for automotive/consumer durables), Industrial Solutions (up 25% yoy; strong demand in polymers/packaging and other industries), Nutrition & Care (up 24.9% yoy; healthy consumer expenditure on home/personal care accentuated by Covid-19 concerns) and Agriculture (up 8% yoy; much better placed including product additions). Chemicals segments delivered substantial growth of 66% on a yoy basis, led by pent-up demand in key end-user industries. Surface Technologies, although down 58% yoy, was up 18.5% sequentially, led by recovery in automotive and construction industry.

Enormous margin improvement led by favorable operating environment: Reported EBITDA (up 6x yoy to Rs2.3bn) was the best in class operating performance delivered by the company, led by enhanced segment performance, further aided by lower employee and other costs (as % of sales). Large part of margin gains came in from divisions such as Materials (12.7% vs. -1% CPLY), Industrial Solutions (12.8% vs. 2.6%) and Nutrition & Care (8.3% vs. -4.9%). We believe that such gains are predominantly driven by lower feedstock costs witnessed in early to mid FY21 due to Covid-19, allowing inventory benefits in the recent quarter, as per our understanding. This was further aided by a better product mix and internal costs control initiatives. However, we believe that margin benefits arising from low cost inventory are temporary in nature and likely to normalize going ahead.

Margin sustenance remains crucial; maintain Buy: We remain positive on the overall growth trajectory of the business and believe that sustaining the positive performance in Materials and Industrial Solutions is crucial to the long-term growth prospects. Factoring in margin improvement of 80-110bps on operational improvement, we raise our EPS estimates for FY22/23 by 19-23% and arrive at a revised TP of Rs1,940 (28x FY23E) from Rs1,630 earlier. We maintain Buy, with EW stance in EAP. Key risks: Downturn in Materials and Industrial Solutions businesses; slowdown in economic revival.

Please see our sector model portfolio (Emkay Alpha Portfolio): Speciality Chemicals (page 9)

Financial Snapshot (Consolidated)

(Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	60,257	75,511	87,286	95,656	1,06,178
EBITDA	1,215	2,405	5,136	5,437	6,460
EBITDA Margin (%)	2.0	3.2	5.9	5.7	6.1
APAT	817	185	2,376	2,396	2,995
EPS (Rs)	18.9	4.3	54.9	55.3	69.2
EPS (% chg)	(66.8)	(77.3)	1,183.8	0.8	25.0
ROE (%)	5.9	1.3	13.9	11.2	12.5
P/E (x)	90.3	398.6	31.0	30.8	24.6
EV/EBITDA (x)	68.7	34.1	15.4	14.6	12.0
P/BV (x)	5.2	5.3	3.6	3.3	2.9

Source: Company, Emkay Research



Your success is our success

СМР	Target Price
Rs 1,704 as of (February 10, 2021)	Rs 1,940 (▲) ^{12 months}
Rating	Upside
BUY (■)	13.8 %

Change in Estimates

Change in Estimate	S		
EPS Chg FY21E/FY2	22E (%)	71.6/2.7
Target Price change	(%)		19.0
Target Period (Month	ıs)		12
Previous Reco			BUY
Emkay vs Consens	us		
EPS Es	timate	s	
	FY	21E	FY22E
Emkay	5	54.9	55.3
Consensus	3	32.0	44.9
Mean Consensus TP	' (12M)		Rs 1,380
Stock Details			
Bloomberg Code			BASF IN
Face Value (Rs)			10
Shares outstanding (mn)		43
52 Week H/L		1	,875 / 795
M Cap (Rs bn/USD b	n)		74 / 1.01
Daily Avg Volume (ne	os.)		45,707
Daily Avg Turnover (US\$ mi	า)	1.0
Shareholding Patte	rn Dec	'20	
Promoters			73.3%
Flls			1.7%
DIIs			7.2%
Public and Others			17.7%
Price Performance			
(%) 1M	3M	6N	I 12M
Absolute -	14	29) 74
Rel. to Nifty (5)	(6)	(5)) 39
Relative price chart	:		
1725 _{Rs}	4		. № [¹⁰⁰
1540 - M	MA	1	₩ [₩] - 78
1355	9482	-W/	My 56
1170 -	N		- 34
985 -			- 12
800 + Feb-20 Apr-20 Jun-20 Au	g-20Oct-2	20Dec	
BASF India (LHS)		— Rel t	o Nifty (RHS)
Source: Bloomberg			
This roport is calaby produ	cod by F	mka	Global The
This report is solely produ following person(s) are res	sponsible	fort	
production of the recomm	endation		
Rohit Sinha			


Rohit Sinha

rohit.sinha@emkayglobal.com +91 22 6612 1306

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


Story in Charts

Exhibit 1: Agriculture and Nutrition aid significant revenue growth




Source: Company, Emkay Research

Exhibit 3: Margins track higher on better product mix and cost initiatives




Source: Company, Emkay Research


Exhibit 5: Most segments in positive territory; EBIT (Rs mn)



Source: Company, Emkay Research


Exhibit 7: Crude prices vital to margins






Source: Company, Emkay Research

Exhibit 4: Nutrition & Care and Agriculture grow yoy (Revenue contribution)




Source: Company, Emkay Research

Exhibit 6: Materials and Surface Tech. recover sequentially; EBIT margin %



Source: Company, Emkay Research

Exhibit 8: USD/INR depreciation aids margins



Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

1.0

74.0

0.2

-35.5

84

10,954

Exhibit 9: Actual vs. Estimates (Q3FY21)

(in Rs Mn)	Actual	Estimate Emkay	% Variation Emkay	Comment
Sales	24244	22781	6.4	Above estimate due to better than expected growth in certain segments
EBITDA	2313	1255	84.3	Above estimates on higher sales base and significant margin
EBITDA margin %	9.5	5.5	400 bps	improvement, along with lower employee and other expenses
Reported PAT (excl. exceptional items)	1091	537	103.1	Above estimates on higher operating income base
Courses Company, Embau Decearch				

Source: Company, Emkay Research

Exhibit 10: Quarterly performance (standalone)

	-	-	0 (5) (0)	00510		M M (0/)	0.0 (0)			V V X
Rs Mn	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	YoY (%)	QoQ (%)	9MFY21	9MFY20	YoY %
Revenue	20,144	18,486	17,697	23,958	24,244	20.4	1.2	65,899	57,025	15.6
Operating Expenditure	16,941	14,878	15,102	19,719	19,444	14.8	(1.4)	54,264	46,459	16.8
Gross Profit	3,203	3,608	2,595	4,239	4,800	49.9	13.2	11,635	10,565	10.1
as % of sales	15.9	19.5	14.7	17.7	19.8			17.7	18.5	
SG&A expenses	2,810	2,850	2,443	2,662	2,487	(11.5)	(6.6)	7,592	8,594	-11.7
as % of sales	14.0	15.4	13.8	11.1	10.3			11.5	15.1	
EBITDA	393	758	152	1,577	2,313	488.5	46.7	4,042	1,971	105.1
Depreciation	465	424	427	430	419	(9.9)	(2.5)	1,277	1,376	(7.2)
EBIT	(72)	334	(275)	1,147	1,894	Nm	65.1	2,766	595	364.8
Other Income	38	121	20	26	48	26.0	85.4	94	156	(39.5)
Interest Expenses	207	159	122	86	63	(69.8)	(26.9)	270	675	(59.9)
PBT	(240)	295	(378)	1,088	1,880	Nm	72.9	2,590	76	3,307.2
Total Tax	(65)	(112)	(87)	1,214	789	Nm	(35.0)	1,917	(27)	(7,198.5)
Adjusted PAT	(175)	407	(292)	(126)	1,091	Nm	Nm	673	103	553.3
Extra ordinary items	149	3	-	(4,236)	-	Nm	Nm	(4,236)	322	Nm
Reported PAT	(324)	404	(292)	4,110	1,091	Nm	(73.5)	673	103	553.3
Reported EPS (Rs)	(7.5)	9.3	(6.7)	94.9	25.2	Nm	(73.5)	113	(5)	Nm
Margins (%)						(bps)	(bps)			(bps)
EBITDA	2.0	4.1	0.9	6.6	9.5	759	296	6.1	3.5	268
EBIT	-0.4	1.8	-1.6	4.8	7.8	817	303	4.2	1.0	315
EBT	-1.2	1.6	-2.1	4.5	7.8	895	322	3.9	0.1	380

17.2

111.6

4.5

42.0

611

1,478

-1,266

-6,963

Source: Company, Emkay Research

Effective Tax Rate

-1.6

27.2

2.2

-37.8

-1.6

22.9

PAT


Exhibit 11: Segment wise performance (standalone)

Segment Wise (Rs mn)	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	YoY (%)	QoQ (%)	9MFY21	9MFY20	YoY %
Agriculture solutions	1,681	2,032	4,389	4,968	1,829	8.8	(63.2)	11,186	9,109	22.8
Materials	4,316	4,385	1,646	4,244	5,836	35.2	37.5	11,727	12,538	-6.5
Industrial Solution	3,209	2,757	2,150	2,978	4,012	25.0	34.7	9,141	9,162	-0.2
Surface Technologies	2,431	2,042	915	865	1,024	(57.9)	18.5	2,804	6,447	-56.5
Nutrition & Care	4,851	4,094	5,357	6,075	6,060	24.9	(0.2)	17,491	10,601	65.0
Chemicals	3,133	2,860	2,976	4,471	5,203	66.1	16.4	12,651	7,300	73.3
Others	523	361	263	337	279	(46.7)	(17.2)	879	1,869	-53.0

EBIT- Segment Wise	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	YoY (%)	QoQ (%)	9MFY21	9MFY20	YoY %
Agriculture solutions	(29.9)	74	410	686.7	(86.7)	Nm	Nm	1,010	538	87.8
Materials	(33.4)	-27	-412	(86.1)	741.2	Nm	Nm	243	(347)	-170.0
Industrial Solution	82.1	209	-116	174.5	513.2	525.1	194.1	572	323	76.9
Surface Technologies	78.7	182	-274	(12.8)	(35.0)	Nm	Nm	(321)	248	Nm
Nutrition & Care	(237.7)	-14	69	316.5	504.2	Nm	59.3	889	(200)	Nm
Chemicals	68.3	40	96	154.2	308.3	351.4	99.9	558	208	169.0
Others	99.9	47	35	45.2	41.6	(58.4)	(8.0)	122	211	(42.1)


EBIT Margin(%)-Segment wise	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	(bps)	(bps)	9MFY21	9MFY20	(bps)
Agriculture solutions	(1.8)	3.7	9.4	13.8	(4.7)	-296	-1,856	9.0	5.9	312
Materials	(0.8)	(0.6)	(25.0)	(2.0)	12.7	1,347	1,473	2.1	(2.8)	484
Industrial Solution	2.6	7.6	(5.4)	5.9	12.8	1,023	693	6.3	3.5	273
Surface Technologies	3.2	8.9	(29.9)	(1.5)	(3.4)	-665	-194	(11.5)	3.8	-1,530
Nutrition & Care	(4.9)	(0.4)	1.3	5.2	8.3	1,322	311	5.1	(1.9)	697
Chemicals	2.2	1.4	3.2	3.4	5.9	374	248	4.4	2.8	157
Others	19.1	13.1	13.4	13.4	14.9	-419	150	13.9	11.3	260

Source: Company, Emkay Research



Source: Company, Emkay Research





Source: Company, Emkay Research

Exhibit 14: Revision in Estimates

Rs mn		FY21E			FY22E		FY23E			
KS IIII	Old	New	% Change	Old	New	% Change	Old	Old	% Change	
Revenues	85,937	87,286	1.6	93,184	95,656	2.7	1,03,434	1,06,178	2.7	
EBITDA	3,879	5,136	32.4	4,533	5,437	20.0	5,135	6,460	25.8	
EBITDA margins %	4.5	5.9	140 bps	4.9	5.7	80 bps	5.0	6.1	110 bps	
Net profits	1,384	2,376	71.7	1,945	2,396	23.2	2,519	2,995	18.9	
EPS (Rs)	32.0	54.9	71.8	44.9	55.3	23.3	58.2	69.2	18.9	

Source: Company, Emkay Research

Exhibit 15: Peer comparison

	Price	Mkt Cap	Baaa	TP		Р	E			PB	(x)			EV/E	BITDA	
Company Name	(Rs)	(Rs bn)	Reco	(Rs)	FY20	FY21e	FY22e	FY23e	FY20	FY21e	FY22e	FY23e	FY20	FY21e	FY22e	FY23e
Advanced Enzyme Tech	370	41	Buy	368	32.0	28.7	23.3	20.1	4.9	4.2	3.6	3.1	20.1	18.0	14.3	12.0
Apcotex Industries	176	9	Hold	171	55.0	28.8	26.0	15.4	3.6	3.3	3.1	2.6	28.5	17.2	14.5	9.0
BASF India	1,704	74	Buy	1,940	398.6	31.0	30.8	24.6	5.3	3.6	3.3	2.9	34.1	15.4	14.6	12.0
Camlin Fine Sciences	117	15	Buy	157	46.7	25.6	15.7	12.5	3.5	2.8	2.4	2.0	14.0	12.5	9.5	7.7
GHCL	213	20	Buy	232	5.1	6.1	4.5	3.9	0.9	0.8	0.7	0.6	4.3	4.2	3.1	2.5
Navin Fluorine	2,524	125	Buy	2,834	67.5	56.3	45.0	28.3	8.8	7.9	6.9	5.7	46.5	39.0	32.2	20.9
SRF	5,527	327	Buy	6,173	35.3	29.1	21.0	17.3	6.6	4.9	4.0	3.3	24.5	17.3	13.0	10.7
Tata Chemicals	572	146	Hold	324	2.1	26.7	19.2	15.6	1.1	1.1	1.1	1.0	11.3	12.7	10.6	9.4
Vinati Organics	1,260	129	Buy	1,330	38.7	47.5	36.1	26.5	10.1	8.7	7.4	6.0	31.1	35.5	26.8	19.3

Source: Company, Emkay Research

Key Financials (Consolidated)

Income Statement

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	60,257	75,511	87,286	95,656	1,06,178
Expenditure	59,042	73,106	82,150	90,218	99,718
EBITDA	1,215	2,405	5,136	5,437	6,460
Depreciation	1,471	1,801	1,749	2,031	2,279
EBIT	(256)	604	3,388	3,406	4,181
Other Income	1,826	277	150	150	150
Interest expenses	851	834	339	332	301
РВТ	719	47	3,198	3,225	4,030
Тах	(99)	(139)	822	829	1,036
Extraordinary Items	(1,155)	276	4,236	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	(337)	461	6,612	2,396	2,995
Adjusted PAT	817	185	2,376	2,396	2,995

Balance Sheet

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Equity share capital	433	433	433	433	433
Reserves & surplus	13,696	13,427	19,910	22,176	25,041
Net worth	14,129	13,860	20,343	22,609	25,473
Minority Interest	0	0	0	0	0
Loan Funds	9,811	8,936	6,136	6,136	5,136
Net deferred tax liability	0	0	0	0	0
Total Liabilities	23,940	22,796	26,479	28,745	30,609
Net block	9,992	9,639	11,160	10,129	9,050
Investment	1,814	1,898	1,898	1,898	1,898
Current Assets	26,050	33,474	37,039	40,009	45,547
Cash & bank balance	132	809	960	470	1,659
Other Current Assets	0	0	0	0	0
Current liabilities & Provision	13,916	22,215	23,619	23,291	25,886
Net current assets	12,134	11,259	13,420	16,718	19,661
Misc. exp	0	0	0	0	0
Total Assets	23,940	22,796	26,479	28,745	30,609

Cash Flow					
Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
PBT (Ex-Other income) (NI+Dep)	(1,107)	(230)	3,048	3,075	3,880
Other Non-Cash items	0	0	0	0	0
Chg in working cap	(1,719)	1,552	(2,010)	(3,787)	(1,755)
Operating Cashflow	658	3,214	6,351	640	3,519
Capital expenditure	133	(1,640)	(3,500)	(1,000)	(1,200)
Free Cash Flow	791	1,574	2,851	(360)	2,319
Investments	(366)	(84)	0	0	0
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(381)	(1,531)	(3,271)	(1,000)	(1,200)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(15)	(875)	(2,800)	0	(1,000)
Dividend paid (incl tax)	216	130	130	130	130
Other Financing Cash Flow	(447)	(1,135)	(3,060)	(260)	(1,260)
Financing Cashflow	(231)	(1,005)	(2,930)	(130)	(1,130)
Net chg in cash	46	678	150	(490)	1,189
Opening cash position	86	132	809	960	470
Closing cash position	132	810	959	470	1,659

Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Profitability (%)	FY19	FY20	FY21E	FY22E	FY23E
EBITDA Margin	2.0	3.2	5.9	5.7	6.1
EBIT Margin	(0.4)	0.8	3.9	3.6	3.9
Effective Tax Rate	(13.7)	(298.1)	25.7	25.7	25.7
Net Margin	1.4	0.2	2.7	2.5	2.8
ROCE	6.7	3.8	14.4	12.9	14.6
ROE	5.9	1.3	13.9	11.2	12.5
RolC	(1.2)	2.9	15.5	13.6	15.7
Per Share Data (Rs)	FY19	FY20	FY21E	FY22E	FY23E
EPS	18.9	4.3	54.9	55.3	69.2
CEPS	52.9	45.9	95.3	102.3	121.8
BVPS	326.4	320.2	469.9	522.3	588.4
DPS	5.0	3.0	3.0	3.0	3.0
Valuations (x)	FY19	FY20	FY21E	FY22E	FY23E
PER	90.3	398.6	31.0	30.8	24.6
P/CEPS	33.4	38.5	18.6	17.3	14.5
P/BV	5.2	5.3	3.6	3.3	2.9
EV / Sales	1.4	1.1	0.9	0.8	0.7
EV / EBITDA	68.7	34.1	15.4	14.6	12.0
Dividend Yield (%)	0.3	0.2	0.2	0.2	0.2
	0.0	0.2	0.2	0.2	0.2
Gearing Ratio (x)	FY19	FY20	FY21E	FY22E	FY23E
Net Debt/ Equity	0.7	0.6	0.3	0.3	0.1
Net Debt/EBIDTA	8.0	3.4	1.0	1.0	0.5
Working Cap Cycle (days)	72.7	50.5	52.1	62.0	61.9
Growth (%)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	7.9	25.3	15.6	9.6	11.0
EBITDA	(62.2)	97.9	113.6	5.9	18.8
EBIT	(115.2)	0.0	460.9	0.5	22.8
PAT	(127.9)	0.0	1,333.1	(63.8)	25.0
Quarterly (Rs mn)	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21
Revenue	20,144	18,486	17,697	23,958	24,244
EBITDA	393	758	152	1,577	2,313
EBITDA Margin (%)	2.0	4.1	0.9	6.6	9.5
PAT	(324)	404	(292)	4,110	1,091
EPS (Rs)	(7.5)	9.3	(6.7)	94.9	25.2
Source: Company, Emkay Research	(11)		(,		
Shareholding Pattern (%)	Dec-19	Mar-20	Jun-20	Sep-20	Dec-20
Promoters	73.3	73.3	73.3	73.3	73.3
Flls	2.2	3.6	2.9	1.5	1.7
DIIs	9.1	7.7	7.8	7.1	7.2
Public and Others	15.4	15.4	16.0	18.1	17.

Source: Capitaline

RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
05-Nov-20	1,485	1,630	12m	Buy	Rohit Sinha
25-Aug-20	1,668	1,484	12m	Hold	Rohit Sinha
07-Aug-20	1,326	1,185	12m	Hold	Rohit Sinha
24-May-20	1,054	1,185	12m	Hold	Rohit Sinha
16-Apr-20	1,110	1,055	12m	Hold	Rohit Sinha
12-Feb-20	892	1,055	12m	Hold	Rohit Sinha
07-Feb-20	980	1,115	12m	Hold	Rohit Sinha
06-Jan-20	982	1,115	12m	Hold	Rohit Sinha
11-Nov-19	990	1,115	12m	Hold	Rohit Sinha
10-Oct-19	977	1,217	12m	Buy	Rohit Sinha
30-Apr-19	1,364	1,217	12m	Sell	Amar Mourya
25-Jan-19	1,370	1,217	12m	Sell	Amar Mourya
30-Oct-18	1,656	2,212	12m	Accumulate	Amar Mourya
31-Jul-18	1,938	2,212	12m	Accumulate	Amar Mourya
09-Jul-18	1,894	2,212	12m	Accumulate	Amar Mourya
07-May-18	2,129	2,212	12m	Buy	Amar Mourya

RECOMMENDATION HISTORY CHART



Source: Company, Emkay Research



Analyst: Rohit Sinha

Contact Details

rohit.sinha@emkayglobal.com

+91 22 6612 1306

Sector

Speciality Chemicals

Analyst bio

Rohit Sinha holds a CFA degree and comes with total four years of experience in the Specialty Chemicals sector. He currently covers nine stocks in the Specialty Chemicals space.

Emkay Alpha Portfolio – Speciality Chemicals

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Speciality Chemicals	0.19	0.19	-1%	0	100.00
Advanced Enzyme Tech	0.00	0.00	NA	0	2.24
Apcotex Industries	0.00	0.00	NA	0	1.09
BASF India	0.00	0.00	NA	0	0.91
Camlin Fine Sciences	0.00	0.02	NA	2	8.27
GHCL	0.00	0.01	NA	1	4.94
Navin Fluorine	0.00	0.04	NA	4	22.98
Orient Refractories	0.00	0.01	NA	1	3.83
SRF	0.19	0.09	-53%	-10	47.43
Tata Chemicals	0.00	0.01	NA	1	4.60
Vinati Organics	0.00	0.01	NA	1	3.15
Cash	0.00	0.00	NA	0	0.56

Source: Emkay Research

* Not under coverage: Equal Weight

High Conviction/Strong Over Weight High Conviction/Strong Under Weight

Sector portfolio NAV


	Base					Latest
	1-Apr-19	11-Feb-20	11-Aug-20	10-Nov-20	8-Jan-21	9-Feb-21
EAP - Speciality Chemicals	100.0	144.9	153.0	181.6	213.9	204.2
BSE200 Neutral Weighted Portfolio (ETF)	100.0	148.0	147.8	177.1	209.5	196.7
*Performance measurement base date 1 st A	April 2019					

Source: Emkay Research

Price Performance (%)

	1m	3m	6m	12m
EAP - Speciality Chemicals	-4.5%	12.5%	33.4%	40.9%
BSE200 Neutral Weighted Portfolio (ETF)	-6.2%	11.0%	33.1%	32.9%
Source: Emkay Research				

NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

Emkay Rating Distribution

Expected Return within the next 12-18 months.
Over 15%
Between -5% to 15%
Below -5%
O Be

Completed Date: 10 Feb 2021 22:15:29 (SGT) Dissemination Date: 10 Feb 2021 22:16:29 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of February 10, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of February 10, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the February 10, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the February 10, 2021

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com